{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:13:31Z","timestamp":1791346411390,"version":"4.3.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical obesity is a prevalent chronic disease, significantly increasing morbidity and mortality while impairing quality of life. As diet and physical activity interventions often prove ineffective in the long term, with increasing use of pharmacotherapy, drug shortages and injection aversion present a challenge. The role of oral semaglutide at a dose of 14 mg (registered for type 2 diabetes) as a treatment for obesity in patients without diabetes remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the retrospective real-world study, which included 93 adults without diabetes (57% women, average age 52 years), we assessed whether treatment with 14 mg oral semaglutide over one year is associated with lower body weight, body mass index (BMI), waist circumference, blood pressure, heart rate, and obesity staging according to EOSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 93 subjects recruited, 82 (88%) were receiving oral semaglutide at a dose of 14 mg after one year. After one year of treatment body weight was significantly lower by 5.7% (5.9 kg) in completers, and BMI decreased significantly by an average of 2 kg\/m\u00b2. There was also a significant reduction in waist circumference by 5.5 cm and a decrease in EOSS score by 0.1. Clinically significant weight loss was achieved in 46% of all participants, with rare individuals experiencing a decrease of \u2265 15%. Adverse effects were mostly mild, with nausea reported by 23% and vomiting and diarrhoea by 12% of participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Obesity treatment with oral semaglutide at a dose of 14 mg showed marked interindividual variability, with approximately half achieving clinically significant reductions \u2013 mostly under 10%. Although less effective than injectable therapy, oral semaglutide at a dose of 14 mg had a favorable safety profile and may be suitable in selected clinical scenarios.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1593334","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:12:51Z","timestamp":1748477571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Oral semaglutide for the treatment of obesity: a retrospective real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Mitja","family":"Krajnc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne\u017ea","family":"Kuhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrijana","family":"Koceva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet"},{"key":"B2","unstructured":"Determinante zdravja \u2013 dejavniki tveganja: \u010dezmerna hranjenost in debelost\n          \n          Ljubljana\n          NIJZ, Zdravstveni statisti\u010dni letopis Slovenije\n          \n          2022"},{"key":"B3","unstructured":"Obesity classification\n          \n          London, UK\n          World Obesity Federation\n          World obesity federation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.amjcard.2017.12.038","article-title":"Relation of waist-hip ratio to long-term cardiovascular events in patients with coronary artery disease","volume":"121","author":"Medina-Inojosa","year":"2018","journal-title":"Am J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/obr.12836","article-title":"A comprehensive diagnostic approach to detect underlying causes of obesity in adults","volume":"20","author":"van der Valk","year":"2019","journal-title":"Obes Rev"},{"key":"B6","unstructured":"NICE guideline\n          \n          London, UK\n          National Institute for Health and Care Excellence\n          Overweight and obesity management"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/nu16203433","article-title":"Complementary role of BMI and EOSS in predicting all-cause and cause-specific mortality in people with overweight and obesity","volume":"16","author":"Bioletto","year":"2024","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000496183","article-title":"European practical and patient-centred guidelines for adult obesity management in primary care","volume":"12","author":"Durrer Schutz","year":"2019","journal-title":"Obes Facts"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000442721","article-title":"European Guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"key":"B11","volume-title":"Strokovna priporo\u010dila za zdravljenje debelosti z zdravili (Professional Guidelines for the Pharmacological Treatment of Obesity)","author":"Jane\u017e","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","unstructured":"Wegovy summary of product characteristics"},{"key":"B14","unstructured":"Ozempic Summary of Product characteristics"},{"key":"B15","unstructured":"Rybelsus Summary of Product characteristics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w.","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14054","article-title":"Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes Obesity Metab"},{"key":"B18","unstructured":"Rybelsus highlights of prescribing information"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"NEJM"},{"key":"B21","unstructured":"Novo Nordisk\u2019s Ozempic shortage expected to continue into Q4\n          \n          New York, US\n          Reuters\n          \n          2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.2","article-title":"A proposed clinical staging system for obesity","volume":"33","author":"Sharma","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"B24","unstructured":"Serious adverse reaction"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight or obesity with-out diabetes. The STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/db24-2084-LB","article-title":"2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)","volume":"73","author":"Hankosky","year":"2024","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration\u2014A danish cohort study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1593334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:12:54Z","timestamp":1748477574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1593334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":31,"alternative-id":["10.3389\/fendo.2025.1593334"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1593334","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"1593334"}}